Overview

A Thorough QT Study of Telotristat Etiprate

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that telotristat etiprate does not differ from placebo in the mean change from Baseline QT interval corrected for heart rate.
Phase:
Phase 1
Details
Lead Sponsor:
Lexicon Pharmaceuticals
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination